Wolverine legal status, FDA 503A category, and compounding access

Where the Wolverine constituents stand today

Wolverine legal status comes down to the status of its two constituents, and both sit in the same place. Under the U.S. Federal Food, Drug, and Cosmetic Act, BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" are each FDA 503A Category 2 bulk drug substances, a placement effective with FDA's September 29, 2023 update to the list of substances nominated for use under section 503A ^[14]. Neither is an FDA-approved drug, and the blend has no approved therapeutic indication.

Looking ahead, access to compounded preparations of these substances is under active FDA review and could change in 2026, but no such change has occurred. Both BPC-157 and TB-500 appear on the published agenda of the Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as substances "being considered for inclusion on the 503A Bulks List" ^[16]. That is a scheduled evaluation and discussion — advisory, not a final decision — and its outcome is unknown. Nothing here should be read as a reclassification having happened, or as carrying any particular date or result ^[16].

What FDA 503A Category 2 means

Drug compounding in the U.S. runs through two sections of the law. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[15].

A compounder may use a bulk drug substance — an active ingredient used as a starting material rather than a finished approved drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet listed are evaluated by FDA through a public nomination process ^[15].

FDA's interim policy sorted nominated substances into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances are those FDA identified as raising significant safety risks; they are not covered by that enforcement-discretion policy, and FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[15]. For both Wolverine constituents, FDA cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization ^[14]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories; substances already in Category 1 may continue under the interim enforcement-discretion policy, while Category 2 substances are not afforded that discretion ^[15].

How compounding access works in general

In general terms, a legally compounded medication is prepared only after an individual patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription. The preparation is then made by a state-licensed 503A compounding pharmacy or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[15]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription issued, but it does not change which substances are eligible to be compounded or remove the need for a legitimate prescriber-patient relationship ^[15].

The ingredient-eligibility caveat is the part that matters here. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules; ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[15]. Because BPC-157 and the TB-500 fragment are currently Category 2, that eligibility is the open question the July 2026 PCAC discussion concerns ^[14][16]. This page names no pharmacy, clinic, or provider, and describes no dose — it is a description of the regulatory landscape, not a route to obtain anything.

Common questions about Wolverine's legal status

Is Wolverine legal?

The Wolverine blend has no approved therapeutic indication, and neither constituent is an FDA-approved drug. BPC-157 and the TB-500 / thymosin beta-4 fragment are each FDA 503A Category 2 bulk substances as of the September 29, 2023 update — identified as potentially presenting significant safety risks and not within FDA's enforcement-discretion policy for compounding ^[14]. This is general regulatory information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

BPC-157 is currently an FDA 503A Category 2 bulk drug substance, meaning FDA identified it as potentially presenting significant safety risks and stated it is not within the enforcement-discretion policy for 503A compounding ^[14]. Access to any compounded preparation depends on a licensed-prescriber evaluation, a valid prescription, and the ingredient being eligible under the 503A/503B rules — and that eligibility is what FDA is still evaluating ^[15][16].

What is the FDA 503A status of Wolverine?

The blend itself has no approved indication. Its two constituents — BPC-157 and the TB-500 / thymosin beta-4 fragment — are each FDA 503A Category 2 bulk drug substances effective with the September 29, 2023 update ^[14]. Both are on the scheduled July 23-24, 2026 PCAC agenda as substances being considered for the 503A Bulks List, which is an evaluation step, not a listing decision ^[16].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use ^[14]. Both are also prohibited in sport by the World Anti-Doping Agency: BPC-157 falls under the S0 non-approved-substances category, and TB-500 / thymosin beta-4 falls under prohibited peptide and growth-factor categories — prohibited in and out of competition for the relevant classes.